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During wakefulness, extracellular levels of metabolites in the brain increase. These include amyloid beta
(Ab), which contributes to the pathogenesis of Alzheimer's disease (AD). Counterbalancing their accu-
mulation in the brain, sleep facilitates the removal of these metabolites from the extracellular space by
convective ﬂow of the interstitial ﬂuid from the para-arterial to the para-venous space. However, when
the sleep-wake cycle is disrupted (characterized by increased brain levels of the wake-promoting neu-
ropeptide orexin and increased neural activity), the central nervous system (CNS) clearance of extra-
cellular metabolites is diminished. Disruptions to the sleep-wake cycle have furthermore been linked to
increased neuronal oxidative stress and impaired bloodebrain barrier function e conditions that have
also been proposed to play a role in the development and progression of AD. Notably, recent human and
transgenic animal studies have demonstrated that AD-related pathophysiological processes that occur
long before the clinical onset of AD, such as Ab deposition in the brain, disrupt sleep and circadian
rhythms. Collectively, as proposed in this review, these ﬁndings suggest the existence of a mechanistic
interplay between AD pathogenesis and disrupted sleep-wake cycles, which is able to accelerate the
development and progression of this disease.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Regulation of amyloid and tau levels in the brain across the
sleep-wake cycle
The aggregation of amyloid beta (Ab) peptides (predominantly
Ab peptides 1e40 and 1e42; Ab40 and Ab42, respectively) into
plaques in the brain is a marker of Alzheimer's disease (AD) and a
key component of the ‘Amyloid cascade hypothesis’ [1]. In recent
years, increasing evidence has accumulated to support the hy-
pothesis that the production of Ab peptides in the brain is closely
connected to the 24-hr sleep-wake cycle, with high extracellular
levels during wakefulness and low extracellular levels during sleep
[2e4] (Fig. 1). A major driver for the production of Ab appears to be
neuronal activity, which is higher during wakefulness as compared
with sleep. This hypothesis is supported by the observation that
unilateral vibrissal stimulation increases, while unilateral vibrissal.se (J. Cedernaes), Ricardo.
euro.uu.se (C. Benedict).
Ltd. This is an open access article uremoval decreases, interstitial ﬂuid (ISF) levels of Ab in the
contralateral barrel cortex of transgenic mice (Tg2576) [5]. In
humans, ISF Ab concentrations have been shown to increase in
patients with acute brain damage as neurological status improves,
and conversely to fall when neurological status declines [6].
During sleep, the brain remains metabolically and electrically
active with preservation of cortico-cortical connectivity during
light sleep, i.e., non-rapid eye movement (NREM) sleep stage 1 (N1)
and NREM sleep stage 2 (N2) [7e9]. However, a reduction occurs in
fronto-parietal functional connectivity with increasing depth of
NREM sleep to the point of being signiﬁcantly reduced in deep
sleep [7e11], also called NREM sleep stage 3 (N3) or slow-wave
sleep (SWS). Therefore, Ab production could be postulated to
decrease during SWS by virtue of the decreased neuronal activity in
this sleep stage. Supporting this hypothesis, cerebrospinal ﬂuid
(CSF) Ab42 levels have been shown to be lowest in humans at
around 10:00 h (around 25% lower than peak values), corre-
sponding to a nadir in ISF levels at 04:00 h (as there is a 6-h lag for
brain soluble Ab to reach the lumbar space [12,13]). This represents
a time point after which most SWS has typically occurred and afternder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Ab amyloid beta
Ab40 amyloid beta peptide 1e40
Ab42 amyloid beta peptide 1e42
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AQP4 aquaporin-4
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ISF interstitial ﬂuid
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Fig. 1. Temporal association between homeostatic sleep pressure and CSF concentrations of amyloid beta. The propensity to sleep is considered to be regulated by two interacting
mechanisms: a circadian process (C) and a homeostatic process (S) [110]. Process C drives arousal and helps time the onset of normal sleep (driven by e.g., environmental light
changes and meal patterns), whereas Process S drives sleep pressure and increases as wakefulness continues and decreases during slow-wave sleep (SWS), a sleep stage that
predominates during the ﬁrst 1/3 of the night. In humans, in a study where samples were collected via an indwelling lumbar catheter, both CSF Ab40 and Ab42 ﬂuctuated by 25%
with a diurnal pattern (labeled as Ab in the ﬁgure) (higher during wakefulness and lower during sleep), with the lowest Ab42 levels at around 10:00 h [2]. This corresponds to
approximately 04:00 h in sleep time as there is a 6-h lag for brain Ab to reach the lumbar space [12,57]. Abbreviations: Ab, amyloid beta; Ab40, amyloid beta peptide 1e40; Ab42,
amyloid beta peptide 1e42 CSF: cerebrospinal ﬂuid.
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movement (REM) sleep.
Neuropeptides involved in the regulation of the sleep-wake cycle
may additionally contribute to the characteristic 24-hr pattern of Ab
peptides in the brain. One such candidate is the hypothalamic neu-
ropeptide orexin-A (hypocretin 1), the level of which increases
during wakefulness [14]. A study in transgenic APPswe (Tg2576)
mice e a mouse model of AD pathology, which carries the Swedish
mutation (K595N/M596L) of the amyloid precursor protein (APP)
resulting in higher Ab peptide levels, and which does not develop
behavioral signs of AD e showed that intracerebroventricular
administration of orexin at the beginning of the light (i.e., inactive)
period could acutely increase both wakefulness and Ab levels in ISF.
Conversely, intracerebroventricular treatment over 24 h with a dual
orexin receptor antagonist (almorexant) decreased Ab ISF levels [2].
Further supporting the role of orexin for Ab accumulation, daily
treatment with almorexant for 8 w reduced the formation of Ab
plaques in several brain regions in APPswe/PS1dE9 mice [2]. In a
recent study performed in amyloid transgenic mice in which theorexingenewasknockedout (APP/PS1dE9/OR/) [15], lossof orexin
resulted in decreased wakefulness and a subsequent reduction in
amyloidpathology. Incontrast toﬁndingsof animal studies, evidence
from human studies about the role of orexin in the regulation of Ab
production in the brain is less consistent [16e23]. For instance, a
recent study involving patientswith the sleep disorder narcolepsye
a disease hallmarked by a progressive loss of brain orexin function
[24]e revealed that CSF concentration of Abwas signiﬁcantly higher
in the patient groupwith normal CSF orexin-A concentration than in
thosewith loworexin-A concentrations [16].Moreover, in a separate
study, CSF levels of Ab42 were found to be lower in narcoleptic pa-
tients compared with healthy controls [25]. Finally, in a case of
narcolepsy-cataplexy that occurred post H1N1 vaccination, a strong
decrease in CSF beta-amyloid was observed (152 mg/l, normal
>500 mg/l [26]). In contrast to these studies involving narcoleptic
patients, CSF concentrations of orexin-A and Ab42 have been found
toshownorelationship inbothADpatients andhealthycontrols [20].
Another key component of AD pathogenesis is the accumulation
of intracellular neuroﬁbrillary tangles (NFTs) composed of
J. Cedernaes et al. / Sleep Medicine Reviews 31 (2017) 102e111104hyperphosphorylated tau (P-tau) protein. Importantly, to date it is
not known if the parenchymal levels of tau in the CNS exhibit the
same 24-hr rhythmicity as Ab. Notwithstanding, neuronal activity
rapidly increases extracellular tau in mice [27], suggesting that
mammalian ISF levels of tau may exhibit a similar neuronal
activity-driven 24-hr sleep-wake pattern as Ab.
Disruptions to sleep and circadian rhythms and the risk of AD
Given the evidence above, an obvious question is: do chronic
disruptions to the sleep-wake cycle increase the risk of AD in
humans? An increasing number of studies support such a notion, as
insomnia [28], self-reported sleep disturbances [29], a decline in
sleep duration [30], impaired sleep consolidation [31], delayed or
decreased circadian rhythms [32], and sleep disordered breathing
(SDB) [33], all have been shown to increase the risk of AD (for a
detailed review, see [34]). While AD itself may cause sleep dis-
ruptions, the fact that sleep disruptions increase AD risk in non-
demented older humans, supports the hypothesis that a chroni-
cally disrupted sleep-wake cycle can drive AD pathogenesis. Pre-
sent evidence from human and animal experiments lends further
support to this hypothesis. Experimentally induced sleep disrup-
tions, to date almost exclusively carried out in rodent models, lead
to an accumulation of AD-promoting metabolites Ab and tau in the
brain [2,3,35e37], increase central nervous system (CNS) oxidative
stress [38e40], and reduce the structural and functional integrity of
the bloodebrain barrier (BBB) [41,42], all of which have been hy-
pothesized to promote the development and progression of AD
[1,43,44]. Finally, disrupted circadian rhythms, which have been
found to even occur prior to the clinical onset of AD [45], have also
been linked to neurodegeneration in rodent models [46,47].
Recent results from human and transgenic animal studies also
support the idea that AD pathology itself can lead to sleep and
circadian disruptions. It has for instance been demonstrated that
pathophysiological processes associated with AD, such as Ab
deposition in the brain, alter sleep, as well as disrupt circadian
rhythms [3,48,49]. Since Ab deposition in the brain and cognitive
dysfunctions are detectable years prior to the clinical onset of AD
[50,51] this suggests that disruptions to the sleep-wake cycle may
be a consequence rather than cause of AD pathogenesis. Alterna-
tively, existing evidence leads us to propose that there exists a
mechanistic interplay between AD pathogenesis and disruptions to
sleep and interrelated circadian rhythms (as illustrated in Fig. 2).
With this in mind, the objective of our review is to systemati-
cally frame recent experimental ﬁndings from human and animal
experiments into a comprehensive overview on candidate mech-
anisms through which chronically disrupted sleep-wake cycles
(e.g., fragmented sleep and circadian disruption) drive AD patho-
genesis, and vice versa.
While there are several recent reviews on sleep-wake cycle
disruptions and CNS deposition of Ab peptides [52e56], to our best
knowledge no one has yet comprehensively reviewed the recent
literature including the role of tau and detailing the wider range of
candidate mechanisms that may underlie the harmful association
between sleep-wake disruptions and risk of AD.
Candidate mechanisms underlying the association between
sleep-wake disruptions and Alzheimer's disease
Clearance of AD-promoting metabolites from the brain
Soluble Ab levels are higher in the brain during wakefulness and
lower during sleep, indicating that sleepmaycurb processes leading
toAbproduction, concomitantlypromotingprocesses involved inAb
clearance [2e4]. In contrast, under conditions of acute sleepdeprivation, brain Ab concentrations further increase during the
night/inactive period, both in mice and in humans [2,35,57]. In one
study, mice were subjected both to acute and chronic sleep depri-
vation.Acute sleepdeprivationduring6hofdaytime (7:00e13:00h)
resulted in around 17% higher ISF Ab levels in Tg2576 mice. Chronic
sleep deprivation of APPswe/PS1dE9 mice, which instead lasted for
21 d, more than doubled Ab levels throughout the brain compared
with control animals [2]. Whereas neither Ab nor tau levels have
been assessed in CSF in more long-term sleep deprivation experi-
ments in humans, several studies have conﬁrmed that sleep in
humans is associated with lower Ab levels in CSF. In a study of 26
healthy men (age 40e60y), the 13 individuals who were allowed to
sleep for one night showed a 6% decrease in CSF Ab42 levels across
the night; an additional correlation analysis showed that total sleep
duration correlated with decreased Ab42 in CSF e neither of these
effectswere seen forAb40, P-tauor total tau (T-tau) [35].Meanwhile,
the 13 subjects who instead underwent sleep deprivation for one
night had no overnight decrease in Ab42 levels in CSF [35]. With
theseﬁndings inmind, thequestion iswhatmechanismedecreased
production or increased clearanceemainly accounts for the drop in
brain Ab levels during sleep, andwhich of the involvedmechanisms
is impaired to the greatest extent during sleep loss?
A recent study suggests that increased clearance during sleep
may be a major driver for the overnight decrease in Ab levels in the
brain. The clearance of Ab is driven by local degradation by a wide
range of proteases [58], phagocytosis by glial cells [59], egress
across the BBB, and Ab reabsorption through the CSF [60]. Recently,
the existence of a CNS paravascular circulation [61] was conﬁrmed
and extended by the use of in vivo two-photon imaging in mice
[62]. It was determined that the CSF acts in the brain parenchyma
like lymph, by ﬂushing out interstitial substances in a process
facilitated by glial cells. It was therefore named the glymphatic (a
glia-dependent lymphatic) system [62]. Subsequently, another
study found that this CSF-ISF exchange increased during sleep in
wild-type mice [37], thereby enabling removal of metabolites that
typically accumulate during wakefulness, encompassing AD-
promoting soluble Ab peptides. During wakefulness, however, the
removal of such metabolites or inert tracers from the brainwas not
as efﬁcient [37]. The study demonstrated that there was a 60% in-
crease in the interstitial space of brain parenchyma in mice during
sleep, as compared with the space found during wakefulness, and
sleep was found to increase the convective ﬂow of ISF from the
para-arterial to the para-venous space [37] (see Fig. 3). The removal
of substances was also greatly increased during sleep, possibly as a
result of the concomitant expansion of the interstitial space, evi-
denced by a doubling in the rate of Ab removal from brain paren-
chyma seen during wakefulness [37]. These effects were
furthermore mimicked by infusion of noradrenergic receptor an-
tagonists, suggesting that low adrenergic input is required for this
convective clearance to occur. In contrast, awakening of sleeping
mice sharply reduced the para-arterial and parenchymal inﬂux of
ISF (reduction of ~95%) [37]. This could suggest that sleep disrup-
tions hallmarked by recurrent awakenings, increased time awake
after sleep onset, or sleep fragmentation due to SDB, may diminish
the ability of the glymphatic system to remove Ab from the brain.
Importantly, a caveat that must be considered is that the study by
Xie et al. utilized exogenously administered Ab to ascertain the
clearance function of the glymphatic system during sleep [37].
Thus, it has not yet been shown to which extent the function of the
glymphatic system during sleep is of relevance for clearance of
endogenously produced Ab. This also applies to a recent human
study, which found MRI-based evidence for modulation of the
extracellular space by sleep and wakefulness. Following 24 h of
wakefulness combined with cognitively demanding task, increased
subcortical but not global gray and white matter volumes were
Fig. 2. Overview of proposed mechanisms through which disruptions to the sleep-wake cycle form a positive feedback loop with AD pathogenesis in humans. Abbreviations: Ab,
amyloid beta; AD, Alzheimer disease; CNS, central nervous system; BBB, bloodebrain barrier; EE, energy expenditure; NFTs, neuroﬁbrillary tangles.
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the brain ventricles, compared with the volumes observed after
normal sleep. These changes reverted after recovery sleep. How-
ever, any relationship to a possible glymphatic system or potential
increased clearance of metabolites during human sleep, as
compared with wakefulness, was not examined [63].
While aggregation of P-tau into NFTs represents the other main
pathologic feature of AD [64], clearance of tau has not been well
characterized. The protein exists in six isoforms, ranging from 352
to 441 amino acids (ten times the size of Ab peptides), without any
known active transport mechanisms to blood like Ab. CSF bulk ﬂow
and in situ degradation are the most likely mechanisms for clear-
ance of tau released into the interstitial space, but a recent study in
mice showed that extracellular tau could also be cleared from the
brain via the glymphatic pathway under anesthesia [65]. To the best
of our knowledge, no study has directly investigated the role of
sleep in the degradation or removal of tau protein from the ISF, and
whether its removal can be impaired by sleep loss. One clinical
study has shown that CSF P-tau or T-tau levels are not affected by
one night of sleep loss in healthy individuals [35], although as noted
by the authors, the long turnover of tau (11 d; [27]) would likely
have required a considerably longer sleep loss paradigm to study
how these dynamics are affected by disrupted sleep.
Because sleep clears cellular waste from the extracellular space
of the brain parenchyma [37], it is nonetheless likely that sleep
promotes tau protein removal from the brain ISF and reduces its
aggregation into NFTs. Suggestive of this, studies using mice that
develop AD pathology (3xTg; produce amyloid plaques and NFTs)
suggest that altered sleep-wake patterns can increase tau levels in
the brain [36,66]. In one of these studies, six weeks of sleep re-
striction for 6 h/day increased cortical Ab and P-tau to about 2-fold
of control animals, although the changes were not signiﬁcant [66].
In another study, two months of sleep disruption by prolongeddaily light exposure (20/4-h lightedark cycle) led to a greater than
50% signiﬁcant increase of the insoluble fraction of tau in the brain,
as compared with control mice that were maintained on a 12/12-
h lightedark cycle [36].
As reviewed in this section, the recent ﬁnding that sleep pro-
motes the function of a glymphatic system, resulting in enhanced
removal of AD-promoting metabolites, is intriguing, but still re-
quires additional research. For instance, it is still unclear whether
sleep-driven clearance of metabolites is also present in humans and
whether it can increase the clearance rate of neurotoxic substances
to the same extent as in mice. Moreover, further research is needed
to disentangle the contribution of normal and disrupted sleep
stages and circadian mechanisms to this function, for example to
address whether interventions that enhance speciﬁc sleep stages
can improve the clearance of metabolites from the brain in subjects
genetically prone to develop AD. Given that activity proﬁles of
neurotransmitter and neuropeptide systems vary across sleep
stages (e.g., high cholinergic activity during REM sleep vs. low
cholinergic activity during SWS [67]) further studies are needed to
ascertain how sleep stage-speciﬁc neurotransmitter and neuro-
peptide patterns contribute to the clearance of AD-promoting
metabolites from the ISF. A recent study demonstrated that when
old (18-month-old) and young (2- to 3-month-old) mice were
compared, the older mice exhibited a marked reduction in the CSF-
ISF exchange, with a 27% reduction in the pulsatility in arterioles in
the brain, and a loss of perivascular aquaporin-4 (AQP4) polariza-
tion [68]. Furthermore, the older mice exhibited a 40% reduction of
their ability to clear Ab that had been injected intraparenchymally
[68]. However, no age-associated decline was seen in the ability of
sleep to increase the interstitial space. This suggests that deterio-
ration of this part of the glymphatic system does not contribute to
the age-associated increase in the risk of AD, to which disrupted
sleep may contribute. However, the inﬂuence of sleep deprivation
Fig. 3. Scheme illustrating the glymphatic system (primarily based on [37]). Akin to
other cells in the body, brain cells are surrounded by interstitial ﬂuid (ISF), which con-
tains nutrients, proteins and other solutes essential for brain cell survival, but also
includes extracellular waste molecules that may be neurotoxic if not cleared properly
(e.g., amyloid beta, Ab). By utilizing real-time assessments of tetramethylammonium
diffusion and two-photon imaging in mice, a brain-speciﬁc system with a similar
function as lymph vessels, for removing ISF from the brain, was discovered in 2012 [62],
and termed the “glymphatic” system as it depends on glial cell functioning. This system
promotes clearance of solublemetabolites from the brain [37,62,68,111]. Following entry
of CSF through the para-arterial space that surrounds penetrating arteries in the brain,
CSF exchangeswith parenchymal ISF, moving across the parenchyma. ISF and interstitial
solutes are then cleared via exit into the para-venous space surrounding large-caliber
cerebral veins [62]. This system was found to depend on the function of astroglial cells
that express the protein aquaporin-4 (AQP4; a water channel), in a highly polarized
manner along the cells' perivascular endfeet, thus ensheathing the cerebral vasculature.
When AQP4 was deleted, CSF inﬂux decreased, coupled with a 70% reduction in ISF
solute clearance. This suggests that the system is involved in clearance of substances
such as Ab, the clearance of which was also markedly reduced following deletion of
AQP4 [62]. Abbreviations: Ab, amyloid beta; AD, Alzheimer disease; AQP4, aquaporin-4;
CSF, cerebrospinal ﬂuid; ISF, interstitial ﬂuid.
J. Cedernaes et al. / Sleep Medicine Reviews 31 (2017) 102e111106on the glymphatic system in young compared with old mice was
not investigated and as such warrants further investigation.
CNS oxidative stress
In addition to the accumulation and deposition of Ab and NFTs in
the brain, CNS oxidative stress resulting from increases in reactive
oxygen species (ROS) and reactive nitrogen species (RNS) has also
been proposed to promote the development and progression of AD
[43]. In APPswemice, oxidative stress precedes deposition of Ab [69],and evidence of oxidative damage has been observed in human AD
subjects studied postmortem, with the greatest pathology found
early in the disease [70]. Defective mitochondria, which are a major
source of ROS, are seen in AD as well as in what is the greatest risk
factor for AD, i.e., aging, and may contribute to AD pathology by
alteringhowAPPand tauproteinsareprocessed [71]. Conversely,APP
and Ab have been shown to interfere with mitochondrial functions
and enzymes [71], inwhatmaydevelop into a positive feedback loop.
ROS and RNS play essential roles under physiological conditions
(e.g., induction of host defense). However, excessive production of
reactive species can induce cellular stress through lipid peroxidation
and protein oxidation. Once initiated, such oxidative processes can
lead to damage to vital cellular components such as proteins, lipids,
and nucleic acids, which can ﬁnally result in cellular death [43].
Several animal studies have found loss of sleep to increase
oxidative stress in the brain [38,39,72,73], suggesting it might be a
candidate mechanism underlying the association between sleep
loss and AD. For instance, in one such study in mice [72], three
nights of extended wakefulness (via environmental enrichment
during the rest cycle) increased signs of oxidative stress in locus
coeruleus (LC) neurons, as reﬂected by increased production of su-
peroxide. Another study found that sleep loss inmice (for 72 h using
a multiple platform method) increased oxidative stress in the hip-
pocampus and was linked to learning deﬁcits, as both the oxidative
stress and the learning deﬁcits could be prevented if anti-oxidative
agents (N-tert-butyl-alpha-phenylnitrone, vitamin E or melatonin)
were administered prior to the sleep deprivation [73], supporting a
detrimental role for oxidative stress following even short term sleep
loss. It must however be noted that other studies in mice have not
found signs of increased oxidative stress in the cortex using total
sleep deprivation paradigms [74] or following REM sleep depriva-
tion after which whole-brain extracts have been analyzed [75]. One
explanation for these discrepant results could be that oxidative
stress is primarily apparent in brain regions that ﬁre at increased
rates across sustained wakefulness, comprising the LC [72]. Sup-
porting this notion, such brain regions appear to be more sensitive
to cellular damage that can lead to cellular death following sleep
disruptions in humans with and without AD [76,77].
An important question that remains unanswered is how can
sleep loss cause oxidative stress in the brain? One explanation
could be that cellular scavenger mechanisms against reactive spe-
cies are compromised in function. Supporting this notion, three
nights of extended wakefulness were shown to reduce the activity
of sirtuin type 3 (SirT3) in the mouse brain [72]. SirT3 is a nico-
tinamide adenine dinucleotide-dependent enzyme that is localized
to the mitochondrial membrane and which upregulates many
antioxidant defenses. Anti-oxidative mechanisms may also
decrease in certain brain regions following sleep loss, especially in
older animals [78], which also display lower CNS levels of defensive
mechanisms such as lower levels of SirT3 [79].
Blood-brain barrier (BBB) integrity
Neurons demand a nearly continuous supply of energy metab-
olites, as they have only limited energy reserves. This requires a
continuous metabolite exchange between circulating plasma and
the brain. This high rate of molecular exchange, however, also im-
plies that neurons are exposed to many potentially harmful factors
derived from the periphery. To prevent the brain from uncontrolled
entry of blood factors and toxins as well as an unfavorable efﬂux of
CNS metabolites into the periphery, the BBB consists of endothelial
cells lining brain capillaries that tightly regulate the ﬂow of nutri-
ents, ions, and ﬂuids between both compartments. As reviewed in
Ref. [44], BBB dysfunctions (e.g., endothelial loss and loss of tight
junction proteins) have been proposed to contribute to the
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from the brain, lead to increased inﬂux of circulating Ab into the
brain, and elevate expression and processing of the Ab precursor
protein.
Importantly, emerging evidence suggests that sleep disruption
may impair the function of the BBB [41,42]. For instance, six days of
sleep restriction in mice, resulting in a mild 13% increase in total
wake time, led to a reduced expression of tight junction proteins by
BBB endothelial cells [42]. This reduction was paralleled by
increasing paracellular permeability of the BBB to small substances,
which under physiological conditions mainly reach the brain via a
saturable transport system located at the BBB [42]. The expression
of glucose transporter 1 (GLUT1), a protein that mediates glucose
uptake through cerebral BBB micro-vessels, was also reduced
following the sleep restriction paradigm. Importantly, functional
and structural alterations to the BBB have also been found in AD
patients, including reduced expression of GLUT1 [80e82]. Further
highlighting the importance of glucose transport, a recent study
found that GLUT1-deﬁcienct (Slc2a1þ/) mice with APPswe over-
expression had increased BBB permeability, reduced dendritic
spines and cognitive deﬁcits [83].
As the increase in paracellular permeability following six days of
sleep restriction in mice returned to baseline after 24 h of recovery
sleep [42], this however suggests that impaired BBB integrity
following short periods of sleep restriction is a reversible process. It
is currently not known whether sleep restriction-induced BBB
disruptions may accelerate neurodegenerative processes involved
in AD, such as Ab plaque formation. This appears especially relevant
given that a recent study found that preclinical AD mouse models
(e.g., PS2-APP and hTauP301S) do not per se display disrupted BBB
function [84], as assessed by passive antibody uptake into the brain.
This could suggest that the role of the BBB may be dissociated from
the pathogenic burden posed by Ab accumulation on e.g., circadian
rhythms and sleep patterns, whereby BBB disruption (due to e.g.,
sleep restriction) may increase AD pathology, but not vice versa.
Circadian disruption
Accumulating evidence connects disruptions of circadian
rhythms, as frequently found in AD patients [45], but also in shift
workers who are also more likely to be short sleepers [85], to
neurodegeneration and cognitive aging [86,87]. For instance, one
study found that shift workers without the ability to recover for
longer time periods between demanding periods of shift work (less
than ﬁve versus over 14 d of recovery time) had increased temporal
lobe atrophy observed on magnetic resonance imaging [86]. In
addition, a 5-year prospective study of 1282 women found that
delayed peak of activity rhythms, and decreased amplitude and
robustness thereof, conferred an increased risk of mild cognitive
impairment (MCI) or dementia [32].
Recent studies have begun delineating how disrupted circadian
rhythmsmay contribute to neurodegeneration (summarized in [46]
and [47]). Mice with ablated Clock or Bmal1 e genes regulating
central and peripheral molecular clocks e exhibit impaired sleep
parameters. Homozygous Clock mutants sleep approximately 2 h
less than wild-type mice [88], and they exhibit increased signs of
oxidative stress in the brain [89,90]. Neuronal- and glial-speciﬁc
deletion of the master clock gene Bmal1 in mice also increased
neurodegeneration, as evidenced by degeneration of synaptic ter-
minals and impaired cortical functional connectivity, as well as
neuronal oxidative damage and impaired induction of several
redox defense genes, such as Aldh2 and Nqo1 [90]. This was
observed even though such genetically targeted ablation (using a
Nestin-Cre driver) does not fully abolish expression of these clock
genes in the suprachiasmatic nucleus (SCN) e the pacemaker clockthat entrains other circadian oscillators e and accordingly activity
and sleep rhythms remained largely unaffected [90]. Similarly,
disrupting the genetic clock machinery via knockout of Bmal1 or
Per2 has been shown to impair murine hippocampal neurogenesis
by perturbing the conversion of quiescent neural progenitor cells
into newborn neurons in the mouse hippocampus [91].
Although these studies establish a connection between circadian
disruption and neurodegeneration, whichmay be linked to AD, they
leave several gaps in our knowledge warranting further investiga-
tion. For instance: does glial-speciﬁc deletion of master clock genes
(e.g., Bmal1) alter the ability of the glympathic system to remove
AD-promoting metabolites from the brain parenchyma, and as an
extension, to what extent does the glymphatic system depend on
properly aligned circadian rhythms? Circadian rhythmdisturbances
are frequently seen even in patients with preclinical AD [45]. The
possible contribution of circadian disruption to AD disease pro-
gression has been showcased by a study in which bright- vs. low-
light exposure in combinationwith melatonin vs. placebo was used
to study the effect of synchronizing circadian rhythms in over 189
patients, 63% of whom had probable AD, over an average follow-up
period of 15 months. Both bright light and melatonin had positive
effects: the light therapy was for example able to slow cognitive
decline (as measured by the mini-mental state examination) [92].
Thus, it may also be worth investigating if therapeutic synchroni-
zation of the circadian timing system (e.g., through bright light
therapy) can help re-establish circadian Ab dynamics in ISF and CSF
in humans suffering fromcircadian rhythmdisorders or at increased
risk of AD (e.g., ApoE4 carriers), and if such therapies can curb the
development and progression of this disease.
Notably, functional weakening of the circadian system, charac-
terized by phase advance, increased fragmentation and reduced
amplitudes of circadian rhythms, is a well-documented conse-
quence of aging [46]. Given that synchronized activity of multiple
circadian clocks in the brain has been suggested to be critically
important for a number of CNS processes [46], it could be specu-
lated that loss of phase coherence between these CNS clocks due to
normal aging, promotes neurodegenerative processes associated
with AD pathology. Supporting this view, it has been shown that,
when comparing young and elderly adults who were either posi-
tron emission tomography (PET) amyloid positive or negative, 24-h
ﬂuctuations in CSF Ab levels decreased with age and even more in
those who were ‘amyloid positive’ [2,57]. The loss of the dynamic
pattern was more pronounced for Ab42 than for Ab40, most likely
due to its greater propensity to aggregate in amyloid plaques [93].
Disruptions to the sleep-wake cycle as a consequence of AD-related
processes
Multiple lines of evidence suggest that neurodegenerative pro-
cesses associatedwithADcancause sleepandcircadiandisruptions in
humans. This is particularly relevant to the interpretation of ﬁndings
from epidemiological studies investigating the association between
sleep disruption and AD features, as they do not typically account for
the occurrence of preclinical AD in a substantial proportion of
cognitively healthyolder individualswhoare included in such studies
[50,51]. For instance, a recent study involving 45older adults (12with
AD) demonstrated that individuals with AD had fewer intermediate
nucleus neurons than controls at the time of death [76]. The inter-
mediate nucleus is considered as the human homolog of the rodent
ventrolateral preoptic nucleus, a brain region that promotes sleep by
inhibiting wake-promoting brain regions, which include the lateral
hypothalamic area, raphe nucleus, tuberomammillary nucleus and
the LC (for more details concerning the neurobiology of sleep regu-
lation, please see [94]). Additional support for the existence of a
bidirectional rather thanunidirectional linkbetween sleepdisruption
Practice points
Disrupted sleep has been found to be associated with an
increased risk of Alzheimer's disease (AD) through several
mechanisms:
1. Observational studies have found that patients with e.g.,
insomnia or sleep disruptions in mid-life to old age have
an increased risk of pathological changes that precede
AD (e.g., CNS increased amyloid burden, neurofibrillary
tangles), as well as an increased risk of dementia and AD.
2. Sleep restriction results in higher levels of markers that
are associated with AD, increases CNS oxidative stress
and can damage the bloodebrain barrier in mice.
3. Clearance of the AD-promoting Ab peptides is greatly
enhanced during sleep in mice and awakening the mice
disrupts this process.
4. Importantly, patients with impaired cognition or
increased Ab burden also show signs of impaired sleep,
and animal models have shown that Ab deposition can
directly drive impaired sleep, in what can turn into a
positive feedback loop.
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healthy (i.e., non-demented) elders. In this study, it was revealed that
those with high Ab burden in the medial prefrontal cortex (a typical
feature of AD) had lower slow-wave activity (SWA) during NREM
sleep. Furthermore, prefrontal Ab burdenwas found to be associated
with impaired sleep-dependent memory consolidation, most likely
mediated through its effects on NREM SWA [48]. Adding further
support to the hypothesis that amyloid deposition may alter sleep
characteristics in the preclinical stage of AD, three additional studies
performed in younger-old and middle-old cognitively healthy in-
dividuals have reported shorter sleep duration and/or lower sleep
quality to be associated with greater CNS amyloid burden [94e97].
Finally, several studies utilizing post-mortem brain samples of AD
patients have found a substantial decrease of neurons in the central
pacemakerSCNcomparedwithcontrol subjects [98e100].Onerecent
study did not ﬁnd a decrease in two of the major SCN cell neuron
populations in AD vs controls subjects [101], but still found an age-
dependent decrease in SCN neuron numbers in both AD and control
subjects.Notably, therewasstill a3-hdelay incircadianrhythms inAD
compared with control subjects, suggesting damage to input or
downstream output brain regions of the SCN in AD patients. Indeed,
tau pathology is observed in its earliest stages in the sleep-wake
regulating LC [102,103]. Together, these ﬁndings may explain why
AD patients, in addition to their sleep problems, frequently have dif-
ﬁculty maintaining normal circadian rhythms [45].
In line with these clinical ﬁndings, many animal studies also
demonstrate that AD-related features can affect sleep parameters.
For instance, APPswe/PS1de9 mice did not show disrupted diurnal
Ab rhythms in ISF or disrupted sleep-wake before deposition of Ab
(at 3mo of age) comparedwithwild-typemice. However, following
the onset of Ab plaque formation in the brain, the sleep-wake cycle
of these animals markedly deteriorated, evidenced by reduced
NREM and REM sleep, and increased wake time [3]. This indicates
that molecular features of preclinical AD, such as Ab accumulation
in the brain, can lead to sleep disruptions. Evidence also suggests
that tau, as the other mainmolecular driver of AD, can disrupt sleep
in animals. For instance, mice that mimic human tauopathy
(rTg4510) have slower membrane oscillations during SWS and
under anesthesia, indicating that pathological tau accumulation
disrupts such CNS states of highly synchronized synaptic activity
[49]. Finally, reduced NREM sleep and increased sleep fragmenta-
tion have been observed in a phenotypic analysis of a mouse model
that mimics the pathophysiology reminiscent of early, prodromal
AD (PLB1Triple mice) [104].
Transgenic animal studies have further enriched our knowledge
on how AD-related molecular features may contribute to circadian
disruption. For instance, in a study examining Tg2576 mice, the
period of wheel running was increased in constant darkness [105] e
indicating a prolonged circadian period. Furthermore, NREM sleep
contained higher electroencephalogram (EEG) frequencies in the
transgenicmice compared to controls, with transgenicmice failing to
demonstrate the increased delta (1e4Hz) power thatwild-typemice
exhibited in response to sleep loss. Complementing these ﬁndings, a
separate study investigating the role of Ab in the regulation of clock
molecules and circadian rhythm found that a mouse model of AD
pathology (5XFAD, which harbors human APP and PS1 mutations)
exhibited altered circadian rhythms in both young (2 mo old) but
especially in older mice (8 mo), as assessed by both body tempera-
ture and home cage activity [106]. The mice also exhibited altered
SCN expression patterns of the circadian clock genes, e.g., Bmal1,
which through in vitro tests was corroborated to result from Ab-
induced degradation [106]. Similar ﬁndings have also been observed
following overexpression of orthologs of APP cleavage enzymes in
drosophila ﬂies, in which the resulting increase in Ab production
resulted in disrupted circadian rhythms [107].Collectively, evidence from both human and animal studies
provide a strong rationale for hypothesizing that poor sleep and
disrupted circadian rhythms may be a potential early marker of
neuropathology during the long preclinical phase of AD.Conclusions
Observational studies have found that patients with insomnia or
sleep disruptions in mid-life to old age have an increased risk of
pathological changes that precede AD (e.g., CNS increased amyloid
burden, neuroﬁbrillary tangles), as well as an increased risk of de-
mentia and AD. In line with these ﬁndings, experimental studies
have demonstrated that sleep disruptions result in higher levels of
markers that are associated with AD, increase CNS oxidative stress,
can damage the bloodebrain barrier in mice, and disrupt clearance
of AD-promoting Ab peptides. Importantly, patients with impaired
cognition or increased Ab burden also show signs of impaired sleep,
and animal models have shown that Ab deposition can directly drive
impaired sleep. Collectively, current evidence points toward the
existence of a mechanistic loop between AD pathogenesis and dis-
rupted sleep and circadian rhythms.
Given the alarming increase in the number of people who are
afﬂicted by chronic sleep problems [108] and AD pathology [109],
studies with long follow-up periods and repeated observations
initiated prior to the clinical onset of AD are needed to further
disentangle the contribution of sleep and AD pathology in their
intertwined relationship. The ideal longitudinal studies will assess
sleep and circadian rhythmsboth subjectivelyandobjectively (e.g., by
actigraphyandEEG-basedsleepmonitoring), simultaneouslywithAD
biomarkers (CSF biomarker levels, imaging using PETand, potentially,
of glymphatic ﬂow) and AD- and sleep-modulating risk factors, such
as genetics, co-morbidities, exercise and exposure to environmental
light and stress. The extent to which general improvements in sleep,
or e.g., targeted sleep-stage enhancement, can help in lowering the
riskor reversing signs of accelerated cognitive aging,MCI/AD, orother
neurodegenerative diseases represent an important parallel path of
research in this emerging interdisciplinary ﬁeld.
Research agenda
Future research should address the following questions
with regards to sleep and AD pathogenesis:
1. The contribution of sleep disruptions to AD pathogen-
esis, and of AD pathogenesis to sleep disruption in
humans, by conducting long follow-up studies that are
initiated prior to the presence of significant amyloid and
tau burden in the brain that may otherwise conceal the
contribution of each factor.
2. How clearance of metabolites in the CNS is regulated in
humans and what sleep stage(s), circadian and underly-
ing neurobiological mechanisms are the greatest con-
tributors to this function.
3. The extent to which general improvements in sleep, or
e.g., targeted sleep-stage enhancement, can help in
lowering the risk or reversing signs of accelerated
cognitive aging, MCI/AD, or other neurodegenerative
diseases.
4. The impact of genetic variants in influencing the extent
by which sleep disruption can confer an increased risk of
AD.
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